anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic granulomatous disease (CGD) primarily results from inherited defects in components of the nicotinamide adenine dinucleotide phosphate oxidase enzyme complex. These include gene defects in cytochrome B-245/558 subunit α/β and neutrophil cytosolic factors 1, 2, and 4. Recently, homozygous loss-of-function variants in cytochrome B-245 chaperone 1 gene (CYBC1) have been discovered to cause CGD (CYBC1-CGD). Data on variant-proven CGD from low-income countries, the most underprivileged regions of the world, remain sparse due to numerous constraints. Herein, we report the first cohort of patients with CGD from Nepal, a low-income country in the Himalayas' challenging terrain. Our report includes a description of a new case of CYBC1 deficiency who was first diagnosed with CGD at our center. Only a dozen cases of CYBC1-CGD have been described in the literature thus far which have been reviewed comprehensively herein. Most of these patients have had significant infections and autoimmune/inflammatory manifestations. Pulmonary and invasive/disseminated bacterial/fungal infections were the most common followed by skin and soft-tissue infections. Inflammatory bowel disease (IBD) was the most common inflammatory manifestation (median age at diagnosis: 9 years) followed by episodes of recurrent/prolonged fever. Other autoimmune/inflammatory manifestations reported in CYBC1-CGD include acute pancreatitis, hemophagocytic lymphohistiocytosis, systemic granulomatosis, interstitial lung disease, arthritis, autoimmune hemolytic anemia, uveitis, nephritis, and eczema. Our analysis shows that patients with CYBC1-CGD are at a significantly higher risk of IBD-like illness as compared to other forms of CGD which merits further confirmatory studies in the future.
The present invention discloses a targeting anti-glioma protein, a preparation method and applications. The present invention separates out a protein, the sequence of which is an amino acid sequence shown as SEQ ID No: 1. Primers related to genetic engineering insert the nucleotide sequence of chlorotoxin into an expression vector pGEX-6p-1, so that a recombinant expression plasmid is formed; therecombinant expression plasmid transforms colon bacillus Rossetta (DE3), and after cell lysis, the Acp-W2 protein is produced by affinity chromatography, ultrafiltration, desalination and chromatography purification. The Acp-W2 protein has specific targeting effect on gliomas, can effectively inhibit the proliferation of rat gliomas and has targeting anti-glioma effect. The Acp-W2 protein is applicable to the preparation of drugs treating or preventing gliomas. The preparation method of the present invention has the advantages of simplicity, convenient operation, high output and good biological activity.
While the role of dysregulated polymorphonuclear leukocyte (PMN) transmigration in septic mediated tissue damage is well documented, strategies to mitigate aberrant transmigration across endothelium have yet to yield viable therapeutics. Recently, microphysiological systems (MPS) have emerged as novel in vitro mimetics that facilitate the development of human models of disease. With this advancement, aspects of endothelial physiology that are difficult to assess with other models can be directly probed. In this study, the role of endothelial cell (EC) apicobasal polarity on leukocyte trafficking response is evaluated with the µSiM-MVM (microphysiological system enabled by a silicon membrane - microvascular mimetic). Here, ECs are stimulated either apically or basally with a cytokine cocktail to model a septic-like challenge before introducing healthy donor PMNs into the device. Basally oriented stimulation generated a stronger PMN transmigratory response versus apical stimulation. Importantly, healthy PMNs are unable to migrate towards a bacterial peptide chemoattractant when ECs are apically stimulated, which mimics the attenuated PMN chemotaxis seen in sepsis. Escalating the apical inflammatory stimulus by a factor of five is necessary to elicit high PMN transmigration levels across endothelium. These results demonstrate that EC apicobasal polarity modulates PMN transmigratory behavior and provides insight into the mechanisms underlying sepsis.
A double-blind, randomized, multicenter, multinational study evaluated and compared the efficacy and safety of three different regimens for emergency contraception. Subjects were enrolled at 15 sites in 10 countries; the racial/ethnic characteristics of the study population overall were 54% Chinese, 34% Caucasian, and 12% Black or Asian (other than Chinese). 2,381 healthy women with a mean age of 27 years, who needed emergency contraception within 72 hours of unprotected intercourse were involved and randomly allocated into one of the two levonorgestrel groups. A single dose of 1.5 mg of levonorgestrel (My Way) was administered to women allocated into group 1. Two doses of 0.75 mg levonorgestrel 12 hours apart (Plan B) were administered to women in group 2. In the My Way group, 16 pregnancies occurred in 1,198 women and in the Plan B group, 20 pregnancies occurred in 1,183 women. The number of pregnancies expected in each group was calculated based on the timing of intercourse with regard to each woman’s menstrual cycle. Among women receiving My Way, 84% of expected pregnancies were prevented and among those women taking Plan B, 79% of expected pregnancies were prevented. The expected pregnancy rate of 8% (with no contraceptive use) was reduced to approximately 1% with My Way.

Emergency contraceptives are not as effective as routine contraception since their failure rate, while low based on a single use, would accumulate over time with repeated use [see INDICATIONS AND USAGE (1)].

In the clinical study, bleeding disturbances were the most common adverse event reported after taking the levonorgestrel-containing regimens. More than half of the women had menses within two days of the expected time; however, 31% of women experienced change in their bleeding pattern during the study period; 4.5% of women had menses more than 7 days after the expected time.
The present invention belongs to the field of high-polymer materials. Disclosed are a high-polymer vesicle containing aggregation-induced emission molecules, a preparation method therefor and an application thereof. The high-polymer vesicle is mainly formed by means of self-assembly of the aggregation-induced emission molecules and amphiphilic block copolymers; an outer layer and an inner layer of a high-polymer vesicle film are hydrophilic layers, each hydrophilic layer is formed by hydrophilic chain sections in the amphiphilic block copolymers, and a film intermediate layer between the outer layer and the inner layer is formed by hydrophobic chain sections in the amphiphilic block copolymers as well as the aggregation-induced emission molecules. The high-polymer vesicle according to the present invention has a high fluorescence intensity and can meet different fluorescent staining requirements. The preparation method for the present invention is simple and feasible, and at the same time offering high production efficiency and good repeatability. The high-polymer vesicle according to the present invention can be used in related fields such as optical bio-imaging, biological detection and clinical imaging, and high-polymer vesicle research.
A hair kit for beautifying and forming any hair texture is provided. The kit contains a hair treatment concentrate and a hair setting mousse. The hair treatment concentrate contains aged or unaged glyoxal, urea or thiourea, an inert carrier (e.g., water and/or a lower alkanol), and other ingredients. The hair setting mousse contains the concentrate described above, an alcohol, a foaming agent, and a propellant. With thin, fine, or curly hair, the concentrate is applied to the hair roots of the shampooed, rinsed, and towel-dried hair and then the mousse is applied to the hair shaft before the hair is groomed and dried. With thick, coarse, or damaged hair, the mousse is applied first to the shampooed, rinsed, and towel-dried hair, and the concentrate is then applied sparingly to the roots before or after grooming and drying the hair.
Participants will receive a placebo via 2 SC injections at baseline. Placebo will then be administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.
PURPOSE OF REVIEW: Hypertrophic cardiomyopathy (HCM) is one of the most common cardiovascular genetic conditions. Although most patients with HCM typically do well clinically, there is a small but real incidence of sudden cardiac death. A diagnosis of HCM was previously a reason for complete exclusion in sports, particularly competitive sports.However, many of these recommendations are based on expert consensus, and much data has been published in the last decade furthering the scientific knowledge in this area, and allowing athletes who may have been previously excluded the potential to participate in strenuous activities and competitive sports.
RECENT FINDINGS: With recent publications on participation in sports with HCM, as well as an emphasis on shared decision-making, more athletes with HCM are participating in competitive sports, even at a professional level. Even contact sports in the presence of an implantable cardioverter-defibrillator are no longer mutually exclusive in the current era.
SUMMARY: Previous guidelines were likely overly restrictive for patients with HCM. Although there is a risk of sudden death that cannot be ignored, the potential for shared decision making as well as medical guidance are entering a new era in all aspects of medicine, particularly in sports participation.
Despite the fact that nutritional deterioration has been associated with patients' functional impairment, the effect of individualized nutritional support or counselling to outpatients, focussing on ordinary food, have not yet been thoroughly explored (Ravasco P. et al. 2007). A few studies have investigated the effect of nutritional counselling on quality of life (QoL) in cancer patients after discharge (Ovesen et al. 1993, Persson et al. 2002, Isenring et al. 2004, Ravasco et al. 2005a, Ravasco et al. 2005b). However, there is to our knowledge not conducted any studies examining the effect of home delivered meals on QoL and other endpoints in outpatients suffering from cancer.

The overall objective of the study is to measure the effect of energy- and protein enriched home delivered meals vs. habitual diet in malnourished outpatients diagnosed with lung cancer. The intervention diet will consist of optional protein- and energy-dense main and in-between-meals. There will be 22 different main meals and 13 in-between meals to choose between. The meals are prepared by The Nordic Kitchen of Copenhagen University Hospital Herlev. The offered main meals will consist of a selection of warm dishes taken from the ordinary menu. The in-between meals are a collection of the Delights of Herlev (dishes previously shown to increase dietary intake among in-patients). The food will be delivered to the participants' home 3 times per week, and participants can order one warm dish and ad libitum in-between meals for each day.
Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
OBJECTIVES: The main objective of the study to compare the effect of hospitalized and outpatient settings on quality of sleep in children with respiratory tract dysfunction.
METHODOLOGY: A descriptive correlational study was carried out at Dhi-Qar Health Directorate pediatric hospitals. The period of the study was from the November 19, 2023 to March 10, 2024. Purposive sample (non-probability) of 250 children (male and female). A total of (125) children were chosen from the children whose admitted to the hospitals, and a total of (125) children were chosen from the outpatient settings. The study instrument consisted of three parts: the sociodemographic sheet, clinical diagnosis sheet, and sleep quality scale. The questionnaire was modified according to experts' recommendation to use it for children with respiratory tract dysfunction. The questionnaire was evaluated by a panel of 15 experts from diverse medical and nursing professions. Both descriptive and inferential statistics were used to analyze the data.
RESULTS: The study findings that effect outpatient settings have more effect from hospitalized settings on quality of sleep in children with respiratory tract dysfunction (M ± SD = 1.322 ± 0.1522).
CONCLUSION: A study showed that the quality of sleep in children with respiratory tract dysfunction was generally average, whether in hospitalized or outpatient settings, outpatient settings had greater difficulties falling asleep and waking than children in hospitalized.
The invention discloses a traditional Chinese medicine composition for treating exogenous fever of children, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from bupleurum chinense, kudzuvine root, sweet wormwood, large-leaved gentian, dandelion, schizonepeta, cortex lycii radicis, rhizoma anemarrhenae and fructus forsythiae according to a certain proportion. The medicament prepared from the traditional Chinese medicine composition has the characteristics of high cure rate and quick response to infantile exogenous fever. The medicament developed by the invention mainly aims at the infants who suffer from upper respiratory tract infection, bronchitis and pneumonia and have early fever and obvious heat image. The adjuvant therapy is better for the children with herpangina, such as the children with lobar lung and the children with herpangina. The invention can improve the cooling speed and shorten the treatment period.
Newly diagnosed DIPG or DMG patients undergoing neurosurgical biopsy prior to receiving radiation therapy will receive BXQ-350 at the MTD established in Part 1, or the highest planned dose level, and radiation therapy. Excised tumor tissue and plasma samples will be evaluated for SapC levels and pharmacodynamic effects.
The invention provides an imidazole-2-carboxylic acid metal beta-lactamase inhibitor, a preparation method and application thereof, belonging to the field of pharmaceutical chemistry. The structure of the metal beta-lactamase inhibitor is shown as a formula I. The compound provided by the invention has good inhibition effect on metallo-beta-lactamase. In particular, the inhibitory effect of compounds 3,5, 13, 18, 17-a to 19-a, 22-a, 24-a to 26-a, 29-a, 30-a, 34-a, 36-a, 37-a on MBL enzyme VIM-2 was significantly improved as compared with compound 1. In addition, the compound can reverse the drug resistance of drug-resistant bacteria to meropenem, and obviously improve the antibacterial effect of meropenem. The compound provided by the invention can be used for preparing a metal beta-lactamase inhibitor and an antibacterial combined medicament, and has a wide application prospect.
Patients aged 19 years or more who are scheduled to undergo refractive surgery will be included in the study. OCT will be performed at baseline (before surgery), 1 day after surgery and 1 week after surgery. Each patient will be tested 3 times.
No application will be made other than medical treatment. On the first day of the study and at the end of the 4th week, the Infant Motor Performance Test (TIMP) will be used to evaluate the infant's motor performance consisting of postural control and selective extremity movements. Anthropometric measurements of all babies included in the study immediately afterwards; The baby's body weight, height and head circumference will be checked on the first day of the study and at the end of the 4th week. The stress level of babies will be evaluated by looking at cortisol and ACTH (Adrenocorticotropic hormone) hormones.
<P>PROBLEM TO BE SOLVED: To provide a method and a composition for modulating (e.g., reducing) the coding sequence expression in mammals.  <P>SOLUTION: There is provided the method for administering a DNA encoding an RNAi agent, e.g. an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g. the DNA encoding the shRNA to non-embryonic mammals, e.g. via a hydrodynamic administration protocol. Furthermore, there is provided a pharmaceutical preparation comprising the RNAi agent for use in the method. The method and composition find use in a variety of different applications, including academic and therapeutic applications.  <P>COPYRIGHT: (C)2011,JPO&INPIT
INTRODUCTION: Venous thromboembolism (VTE) carries a high risk of recurrence, and this risk is strongly related to the nature of the index event. Thus, extended anticoagulation treatment is recommended for patients with a high recurrence risk and should be considered for patients with an intermediate risk. This study aimed to provide insight into the clinical practice of extended anticoagulation for VTE patients METHODS. This was a retrospective study of VTE patients covering the period from January 2020 through June 2021. We categorised patients by their estimated risk of recurrence as low (less-than 3% per year), intermediate (3-8% per year) or high (> 8% per year). The decision to stop or extend anticoagulation was made in a multidisciplinary VTE clinic.
RESULTS: A total of 343 patients were included; 315 patients were eligible for analysis. The majority of patients (58.7%) had an intermediate recurrence risk. In total 80.3% received extended treatment. The use was highest (97.9%) among patients with a high recurrence risk, whereas 82.7% with an intermediate risk and 15.2% with a low risk received extended therapy. Non-vitamin K antagonist oral anticoagulants were preferred for extended therapy (82.2%), whereas 5.1% received warfarin and 12.6% low molecular weight heparin.
CONCLUSIONS: In this real-world clinic, the majority of VTE patients switched to extended treatment after initial standard anticoagulation. The role of patient and physician preference as determinants driving this decision should be investigated further.
FUNDING: This study received an unrestricted grant from Bayer, which had no involvement in the study design, data collection, analysis, or manuscript preparation.
TRIAL REGISTRATION: Not relevant.
Influenza occurs on an annual basis, producing significant mortality in most years, mainly in those with underlying conditions and those at extremes of age. This study is a placebo-controlled trial to examine efficacies of the live attenuated and inactivated influenza vaccines, and immune correlates of protection; the study will take place in Michigan over a three year period, and will target adults aged 18-49 years. Both vaccine preparations are licensed for this age group. In the first year, participants will be randomly assigned to receive one of the two licensed vaccines or placebo. In the second year, participant receipt of vaccine (updated according to national recommendations) or placebo will continue as assigned in the first year for returning participants, and new enrollees will be randomly assigned to intervention. In the third year, when duration of immunity will be evaluated, no interventions will be given. In all study years, blood specimens for serologic studies and specimens for virus identification will be collected and a number of laboratory studies will be performed so that it will be possible to achieve the study's objectives. The primary annual study outcome for efficacy is the proportion of subjects with laboratory-confirmed symptomatic influenza A or B illness, defined as influenza virus isolated in tissue culture from a throat swab obtained from a participant during an episode of illness meeting the influenza case definition that is confirmed as influenza by fluorescent antibody or polymerase chain reaction (PCR) techniques; or serologic confirmation of influenza infection in a participant with an episode of illness meeting the influenza case definition, specifically a 4-fold rise in hemagglutinin inhibition assay (HAI) antibody titer to a circulating influenza strain between post-vaccination (pre-season) and post-season paired sera. The influenza case definition is illness with at least one respiratory symptom (cough or nasal congestion) and at least one constitutional symptom (fever or feverishness, chills or body aches). Subjects will be evaluated for serious adverse events throughout each annual study period. Annually, the proportion of participants with local reactions during the first seven days or any adverse reactions during the first thirty days after vaccine receipt will be compared with recipients of placebo.
Botulism is a neuro-paralytic syndrome caused by the production of a neurotoxic protein by Clostridium botulinum. It is a rare but potentially fatal poisoning. Symptoms are due to blockage of neurotransmitter release at the neuromuscular junction. Botulism usually occurs following ingestion, inhalation or contact of the toxin with a wound. More recently, cases of iatrogenic botulism have been described, notably following the injection of toxin for therapeutic or cosmetic purposes. In spring 2023, an outbreak of iatrogenic botulism following intragastric injections was reported in Europe. Here, we provide an overview of botulism, followed by a presentation of the only two Swiss cases reported during the epidemic.
Sulfamethoxazole/trimethoprim-induced thrombocytopenia may be an immune-mediated disorder. Severe cases of thrombocytopenia that are fatal or life threatening have been reported. Thrombocytopenia usually resolves within a week upon discontinuation of sulfamethoxazole/trimethoprim.

The sulfonamides should not be used for the treatment of group A β-hemolytic streptococcal infections. In an established infection, they will not eradicate the streptococcus and, therefore, will not prevent sequelae such as rheumatic fever.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including sulfamethoxazole and trimethoprim and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. 

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. 

CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.